Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Molecular Zika Study Finds Possible Target for Tests, Drugs

By Drug Discovery Trends Editor | April 19, 2016

The molecular structure of the Zika virus as seen on x-ray crystallography revealed electrostatic differences in a key protein compared with other flaviviruses that might explain how it infects human cells, according to a study today from Chinese researchers.

In other developments, Peru reported its first sexually transmitted Zika virus case, and public health experts from Mexico described the country’s outbreak and clinical illness pattern.

NS1 surface protein clues

Scientific research to answer the many questions surrounding the explosive spread of Zika virus and its link to birth defects is under way on many fronts, and today’s report on x-ray crystallography findings is the second recent study on its structure. In late March, another team published a detailed viral structure map, which revealed a variation in its surface envelope (E) proteins.

In today’s report, in Nature Structural & Molecular Biology, the researchers from China focused on the nonstructural protein (NS1) of Zika virus, which plays a role in pathogenesis in other flaviviruses such as dengue and West Nile.

Identifying NS1 also helps to diagnose infections, and other research teams are eyeing it as a possible target for antiviral drug development.

In imaging the NS1 fragment, the team used the strain responsible for fueling Brazil’s Zika virus outbreak. They found that it is structurally similar to dengue and West Nile viruses, but the arrangement of the electrical charges on its surface were substantially different.  

The investigators said the difference they saw might relate to host-factor interactions, which should be studied in greater detail, and that other scientists might be able to harness their findings for developing new diagnostic tools.

Sexual transmission case in Peru

In new outbreak developments, health officials in Peru reported the country’s first sexually transmitted Zika case, involving a 32-year-old woman who was infected by her 39-year-old husband who was exposed to the virus while visiting Venezuela, Reuters reported today, citing the Peru’s health minister.

Evidence of the virus was found in the man’s semen, and both patients are recovering from their infections, according to the report.

Peru’s announcement raises the number of countries that have reported cases of sexual Zika transmission to seven.

The World Health Organization (WHO), meanwhile, on Apr 15 acknowledged a sexual transmission case in Chile. The agency said a woman got sick with Zika virus symptoms, including fever and rash, on Feb 4, after her partner was ill with a Zika-like illness after traveling to a country in which local transmission was occurring.

Test results were positive for Zika virus immunoglobulin M (IgM) and IgG for both patients, and the woman’s partner was negative for dengue IgM.

The WHO said sporadic sexual transmission cases will probably continue to be reported, but they don’t change the overall risk assessment, given that the disease is primarily passed through mosquitoes.

Mexico’s Zika outbreak pattern

Elsewhere, epidemiologists from Mexico’s health ministry recently profiled the country’s outbreak, noting that the first two local cases were detected on Nov 25, 2015, and that as of Feb 19, surveillance systems have identified 93 local cases so far. They reported their findings on Apr 15 in Public Library of Science (PLoS) Currents Outbreaks.

One of the first two cases was detected in Chiapas state, the same location that reported the first local chikungunya case the year before. The other was Nuevo Leon, which is near the US border.

Eight Mexican states have reported cases, but Chiapas has been hardest hit, reporting 58.1% of the country’s Zika cases. Oaxaca has reported 27,  Nuevo Leon has reported 4, and Guerro has reported 3. Jalisco, Michoacan, Sinaloa, Veracruz, and Yucatan have each noted 1 case.

Eight of the 93 cases are in pregnant women, with one diagnosed at 34 weeks’ gestation. The woman delivered a healthy baby, according to the report.

Clinically, Mexico’s Zika cases are consistent with those reported in other countries in the Americas. Only two patients were hospitalized, and so far no related Guillain-Barre syndrome cases have been reported, though neck stiffness was reported in two cases.


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50